Johnson & Johnson’s single shot coronavirus vaccine has shown positive immune response during an early trial and seems safe for use, as per a report published on Wednesday.
One dose of the vaccine offers sustainable antibodies, says Chief Scientific Officer at Johnson & Johnson’s, Dr. Paul Stoffels to CNBC. The trial results have provided the company with confidence that this dose of vaccination would be effective, said Stoffels.
The candidate for Johnson & Johnson’s coronavirus vaccine is undergoing Phase 3 trials at present to better understand its effectiveness. The results of the study are believed to be revealed by the end of this month.
If the result are successful and receive a green signal then the vaccine will become the 3rd available vaccine for combating coronavirus that continues to cause havoc in the US as well as other parts of the world.
Almost 400,000 US citizens have passed away from coronavirus, and over 22mn people have contracted the disease.
One vaccine developed jointly by BioNTech and Pfizer won approval for emergency use previous month alongside another vaccine developed by Moderna. The two vaccines need booster shots as follow up and are kept at low temperatures, complicating their distribution.
Notably, the result of the Phase 1 and Phase 2 trials appear in the New England Journal of Medicine.
